These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9609104)

  • 21. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
    Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
    In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of oxaliplatin in the treatment of colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronopharmacology and chronotherapy of cancers].
    Lévi F
    Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of intraperitoneal ormaplatin.
    Plaxe SC; Braly PS; Freddo JL; McClay E; Christen RD; Kirmani S; Kim S; Heath D; Howell SB
    Gynecol Oncol; 1993 Oct; 51(1):72-7. PubMed ID: 8244179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
    Luo FR; Wyrick SD; Chaney SG
    Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
    Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
    Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
    Bleiberg H
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin in colorectal cancer patients living in an arctic or subarctic area: significant cold-triggered dysesthesias and laryngeal reactions.
    Norum J
    J Chemother; 2000 Dec; 12(6):525-9. PubMed ID: 11154038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin-related side effects: characteristics and management.
    Cassidy J; Misset JL
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):11-20. PubMed ID: 12422304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
    Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
    J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum compounds in children with cancer: toxicity and clinical management.
    Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
    Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
    Gamelin E; Gamelin L; Bossi L; Quasthoff S
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
    Gent P; Massey K
    Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.